Labiotech.eu

News and Trends 5 Dec 2022

Bactobio raises £6M to search for new antimicrobials

U.K. biotech company Bactobio Ltd. has closed an oversubscribed £6 million ($7.4 million) bridge financing round. The financing was led by Bridford Group, with support from angel investors Peder Holk Nielsen (former CEO and president of Novozymes) and Hugh Grant (former chairman and CEO of Monsanto). New investors included the founders of the London-based fintech […]

December 5, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 5 Dec 2022

MaxCyte and Curamys sign cell and gene therapies agreement

MaxCyte, Inc. and Curamys have announced the signing of a strategic platform license. MaxCyte is a cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics and to support cell-based research. Curamys is a South Korean biotechnology company developing cell and gene therapy using cell fusion technology […]

December 5, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 5 Dec 2022

Faron Pharmaceuticals provides cancer treatment update

Faron Pharmaceuticals Oy has given an update on its phase I/II BEXMAB study, investigating bexmarilimab. Bexmarilimab is Faron’s wholly owned precision immunotherapy asset, in combination with standard of care (SoC) in multiple hematological malignancies. The Finnish company said an azacytidine-refractory acute myeloid leukemia (AML) patient with partial responses as communicated on October 31, 2022, achieved […]

December 5, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 5 Dec 2022

First subject dosed in inflammation phase I study

Innovent Biologics, Inc. and UNION therapeutics A/S have announced that the first Chinese healthy volunteer has been successfully dosed in the phase I study of orismilast, a potential best-in-class PDE4 inhibitor in global clinical phase II stage. This study is a multiple dose escalation phase I study in healthy volunteers aiming to evaluate the pharmacokinetic […]

December 5, 2022 - 5 minutesmins - By Jim Cornall

News and Trends 5 Dec 2022

Kintor Pharma says alopecia primary endpoint met

Kintor Pharmaceutical Limited has announced results of a phase II clinical trial of pyrilutamide (KX-826), a potential first-in-class topical drug, for the treatment of adult female androgeneticalopecia (AGA). The company said in the study KX-826 demonstrated clinically meaningful and statistically significant improvement in hair growth as measured by target area non-vellus hair count (TAHC). In […]

December 5, 2022 - 3 minutesmins - By Jim Cornall

Interview 5 Dec 2022

Interview: why the recently approved fecal microbiome product is causing a rumble

The news last week of the FDA approving Ferring Pharmaceuticals’ first fecal microbiome product, Rebyota, caused quite a stir in the field. The news was described as a huge step, a giant leap forward and simply fantastic. Paul Feurstadt is the director of non-inflammatory bowel disease research at the Medical Research Center of Connecticut. He also […]

December 5, 2022 - 5 minutesmins - By Liza Laws

News and Trends 2 Dec 2022

Tris Pharma and Pediatrix Therapeutics extend partnership for ADHD portfolio

Tris Pharma, Inc announced today (December 2) that they have expanded their partnership allowing Pediatrix Therapeutics to receive exclusive rights to commercialize its entire FDA-approved ADHD portfolio as well as ADHD pipeline products in China. Tris says it has a robust portfolio of FDA-approached products for the treatment of attention deficit/hyperactivity disorder (ADHD) and a pipeline of treatments […]

December 2, 2022 - 2 minutesmins - By Liza Laws

News and Trends 2 Dec 2022

Partnership to deliver oncology workflow for 7 European hospitals

A BC Platforms (BCP) partnership that includes Finland’s Euformatics and Hungary’s Oncompass Medicine has been awarded a contract for the second phase of developing standardized oncology workflows for a buyer consortium of seven European hospitals, represented by the Medical University Graz. The consortium is formed by hospitals from the Medical University of Graz in Austria, […]

December 2, 2022 - 4 minutesmins - By Jim Cornall

News and Trends 2 Dec 2022

Creating designer immune cells at scale

To prevent testing on animals and create more precise ways of testing therapeutics, the pharmaceutical industry is turning to human immune cells. However, the availability of cells has been limited to date. Now, researchers at the Fraunhofer Institute for Toxicology and Experimental Medicine (ITEM) and Hannover Medical School (MHH) in Germany have succeeded in scaling […]

December 2, 2022 - 4 minutesmins - By Jim Cornall

News and Trends 2 Dec 2022

Full-Life Technologies acquiring Focus-X Therapeutics

Full-Life Technologies, a global radiotherapeutics company, is acquiring New Jersey-based Focus-X Therapeutics, a company developing targeted radiopharmaceuticals to treat cancer based on peptide engineering technology. The acquisition expands Full-Life’s pipeline, including two compounds nearing clinical trials, provides a second innovative peptide focused discovery platform, and leverages its radiotechnology manufacturing and logistics platforms to advance compounds […]

December 2, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 2 Dec 2022

Khondrion’s sonlicromanol produces encouraging results for next stage of study

Biopharma company, Khondrion, has marked announced improvements from patients with MELAS spectrum disorders taking its lead asset, sonlicromanol. Updates were provided by the company from a 28-day double-blind, randomized placebo-controlled, three-way cross-over phase 2b study called KHNERGYZE in which 27 took part. It also reported updates on the ongoing, open-label extension KHEREREXT phase 2b study […]

December 2, 2022 - 2 minutesmins - By Liza Laws

News and Trends 1 Dec 2022

FDA’s approval of first fecal microbiota product, Rebyota, hailed an ‘enormous step forward’ for the field

The first fecal microbiota product, Rebyota, approved by the U.S. Food and Drug Administration (FDA) today has been hailed ‘fantastic news’ by those in the microbiome field. Ferring Pharmaceutical’s product is approved to stop Clostridiodes difficile infection (CDI) in people over 18 and to be given after they have completed an antibiotic treatment for the […]

December 1, 2022 - 6 minutesmins - By Liza Laws

Knowledge hub

Categories

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

Approaches

Therapeutic areas

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Bactobio raises £6M to search for new antimicrobials

MaxCyte and Curamys sign cell and gene therapies agreement

Faron Pharmaceuticals provides cancer treatment update

First subject dosed in inflammation phase I study

Kintor Pharma says alopecia primary endpoint met

Interview: why the recently approved fecal microbiome product is causing a rumble

Tris Pharma and Pediatrix Therapeutics extend partnership for ADHD portfolio

Partnership to deliver oncology workflow for 7 European hospitals

Creating designer immune cells at scale

Full-Life Technologies acquiring Focus-X Therapeutics

Khondrion’s sonlicromanol produces encouraging results for next stage of study

FDA’s approval of first fecal microbiota product, Rebyota, hailed an ‘enormous step forward’ for the field

Subscribe to our newsletter to get the latest biotech news!

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!